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We compared Etest with broth microdilution testing for isavuconazole activity against 92 Cryptococcus
isolates. A 97.8% agreement was found between these methods, without major discrepancies (>2-well dilution
difference). Our findings support the use of the Etest methodology as a reliable method for the determination
of MICs against Cryptococcus spp.
The Clinical and Laboratory Standards Institute (CLSI),
formerly the National Committee for Clinical Laboratory
Standards (NCCLS), has developed and published guide-
lines for broth microdilution (BMD) antifungal susceptibil-
ity testing against yeast (6). These guidelines serve as a
reference standard to facilitate interlaboratory consistency
for antifungal susceptibility testing. Because this method is
labor-intensive, other methods, such as Etest (AB Biodisk,
Solna, Sweden), which employs an antimicrobial gradient on
an agar surface, have been developed to assist in determi-
nation of MICs.
Isavuconazole (formerly BAL4815) is a new triazole with
proven in vitro activity against Aspergillus, Fusarium, Sce-
dosporium, and Candida spp.; the zygomycetes; and Crypto-
coccus neoformans (3, 4, 9, 11). In vivo efficacy in a murine
model of invasive aspergillosis caused by Aspergillus flavus
has also been demonstrated (11). Oral and intravenous for-
mulations have been developed, providing advantages over
similar triazoles, such as posaconazole, which is currently
available only in oral solution, and voriconazole, which has
little activity against the zygomycetes (7). The intravenous
formulation of isavuconazole does not require the addition
of cyclodextrin to achieve solubility, as is required for itra-
conazole and voriconazole, thereby eliminating concerns re-
garding nephrotoxicity due to the cyclodextrin component of
intravenous solutions (8). These factors make isavuconazole
a potentially attractive choice during the care of invasive
mycoses.
The isavuconazole Etest has previously been evaluated
only for Aspergillus and Candida spp. (3). Concordance rates
of 96% and 93% were found between the Etest and BMD
methods for these species. However, the isavuconazole
Etest method has yet to be evaluated for use with Crypto-
coccus spp. In this study, we evaluated the performance of
isavuconazole by comparison of Etest to BMD in accor-
dance with CLSI methodology.
Ninety-two nonduplicate clinical and environmental Cryp-
tococcus isolates (courtesy of B. L. Wickes) were tested (57
C. neoformans and 35 C. gattii isolates), including 67 clinical
strains, 24 environmental strains, and 1 recombinant strain
collected from the United States, Australia, France, Den-
mark, Italy, Thailand, and Zaire over the last 15 years. Prior
to testing, isolates were maintained in sterile water or frozen
in glycerol-supplemented broth. Each isolate was subcul-
tured at least twice on Sabouraud dextrose agar (Remel,
Inc., Lenexa, KS) prior to in vitro susceptibility testing.
Candida krusei ATCC 6258 and Candida parapsilosis ATCC
22019 were used as quality controls in accordance with NCCLS
document M27-A2 (6).
Isavuconazole powder and isavuconazole Etest strips were
supplied by Basilea Pharmaceutica Ltd. For BMD testing,
an isavuconazole stock solution was prepared in dimethyl
sulfoxide and further diluted in RPMI 1640 medium with
L-glutamine and without bicarbonate, buffered to a pH of
7.0 with MOPS (morpholinepropanesulfonic acid). Aliquots
(0.1 ml) of isavuconazole at 2 concentrations were dis-
pensed into 96-well microdilution trays. BMDs were per-
formed in accordance with the M27-A2 reference method.
Inocula containing 0.5  103 to 2.5  103 cells/ml were
prepared spectrophotometrically to the optical density
equivalent of a 0.5 McFarland standard. The inocula were
added, and the trays were incubated at 35°C. The final
isavuconazole concentrations ranged from 0.015 to 8 g/ml.
The MICs were read as 50% reductions in turbidity com-
pared to the levels for the drug-free control tube at 48 and
72 h. This method has been shown to have 95% intralabo-
ratory reproducibility (2).
For the Etest MIC determination, 90-mm-diameter plates
containing RPMI agar (1.5% [vol/vol] agarose) supple-
mented with 2% glucose (RPG medium) were used. The
agar surface was inoculated with isolates prepared as de-
scribed above, using a nontoxic swab dipped in the cell
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suspension. Isavuconazole Etest strips were then applied to
each plate. The plates were incubated at 35°C and read at 48
and 72 h. Comparison of MICs at 48 and 72 h revealed
infrequent changes, with all isolates’ 72-h MICs within 2
dilutions of the recorded 48-h values. For 24 of the isolates,
the 48-h MICs were 1 dilution lower than the corresponding
72-h MICs, while 7 isolates had 48-h MICs 2 dilutions lower
than those recorded at 72 h; no isolates had higher MICs at
48 h than at 72 h. The Etest MICs were read as the points
at which a prominent reduction of growth intersected the
Etest strip (5). MICs obtained from Etest were raised to the
next twofold level of dilution to account for the continuous
gradient of concentrations provided by this modality of test-
ing. Differences of more than 2 dilutions between results for
the BMD and Etest methods were defined as discrepant.
Isavuconazole MICs were consistent with previously re-
ported results for C. neoformans (4). Table 1 summarizes
the in vitro susceptibilities of 92 Cryptococcus isolates. Isa-
vuconazole MICs did not exceed 1 g/ml by either method,
a finding consistent with previously reported susceptibility
testing for extended spectrum triazoles in Cryptococcus iso-
lates (4). Significant differences between MIC50 and MIC90
values were not observed upon comparison of C. neoformans
and C. gattii isolates. Clear zones of inhibition were ob-
served for each isolate at concentrations above the MIC
with the Etest methodology (Fig. 1). The Etest and BMD
results were within 2 dilutions for 90 of the 92 isolates
(97.8%). The first discrepant isolate had an Etest MIC lower
than its BMD MIC (0.004 g/ml [Etest] versus 0.03 g/ml
[BMD]), a difference unlikely to affect clinical decision mak-
ing or outcomes. The other discrepant isolate had an MIC
reported by Etest higher than that reported by the BMD
microdilution method (Etest MIC, 0.125 g/ml, and BMD
MIC, 0.015 g/ml). Similarly, infrequent overestimation of
MICs in Cryptococcus isolates by the Etest method have been
reported for both fluconazole and voriconazole (1, 5, 10).
Our results illustrate the agreement of the Etest method
with BMD for determining in vitro susceptibility of Crypto-
coccus isolates with the new triazole isavuconazole. Etest
provides great assistance to the clinical laboratory for test-
ing multiple antifungal agents concurrently in an efficient
manner. The role of isavuconazole in the treatment of cryp-
tococcosis remains to be defined; however, the in vitro ef-
ficacy determined by BMD and the Etest method suggest
that isavuconazole may be a welcome addition to the grow-
ing antifungal armamentarium.
TABLE 1. Antifungal activity of isavuconazole Etest and BMD
against 92 isolates of C. neoformans and C. gattii
Method Organism(s) GMa MIC range MIC50 MIC90
BMD Total 0.025 0.015–0.5 0.015 0.06
C. gattii 0.027 0.015–0.25 0.03 0.06
C. neoformans 0.024 0.015–0.5 0.015 0.06
Etest Total 0.025 0.002–0.064 0.023 0.064
C. gattii 0.030 0.003–0.064 0.32 0.125
C. neoformans 0.022 0.002–0.5 0.023 0.047
a GM, geometric mean.
FIG. 1. Representative Etest figures demonstrating activity against C. neoformans isolates. Clear zones of inhibition were observed at
isavuconazole concentrations above the MIC.
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